All Photos(1)



(R)-Tomoxetine hydrochloride


Atomoxetine hydrochloride, (R)-N-Methyl-γ-(2-methyl­phenoxy)benzenepropanamine hydrochloride
Empirical Formula (Hill Notation):
C17H21NO · HCl
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:

Quality Level




Eli Lilly

storage temp.


SMILES string




InChI key


Gene Information

human ... SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide


(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:
  • to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice
  • to study its effects on set shifting in rats
  • to study its effects on rat brain as a result of its long-term use


25, 50, 100 mg in glass bottle

Biochem/physiol Actions

(R)-Tomoxetine hydrochloride is an efficient inhibitor of presynaptic norepinephrine transporters. It also positively regulates the release of acetylcholine in the prefrontal cortex (PFC). (R)-Tomoxetine hydrochloride binds to the serotonin (5-HT) transporter. It is involved in blocking the cortical N-methyl-D-aspartate (NMDA) receptors.. (R)-Tomoxetine hydrochloride exhibits therapeutic effects against attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).
Norepinephrine uptake blocker.

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Certificate of Analysis

Certificate of Origin

Fatma Gür et al.
Biochemical and biophysical research communications, 534, 927-932 (2020-11-05)
Attention Deficit Hyperactivity Disorder (ADHD) is the most common psychiatric disorder reported particularly in children. Long-term use of antipsychotic drugs used in the treatment of ADHD has been shown to exert toxic effects on the brain. However, not enough research...
Grazia Dell'Agnello et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 19(11), 822-834 (2009-09-01)
The primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support. This was...
Rachel Kornfield et al.
Psychiatric services (Washington, D.C.), 64(4), 339-346 (2013-01-16)
This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices. Data obtained from the IMS Health National...
Simona Ruggiero et al.
Journal of child and adolescent psychopharmacology, 22(6), 415-422 (2012-12-14)
Our intensive pharmacosurveillance monitoring program was performed to increase the number of adverse drug reactions (ADRs) recorded in the Italian spontaneous reporting database, and to systematically collect more thorough data about atomoxetine (ATX) and methylphenidate (MPH) safety in the pediatric...
Romano Arcieri et al.
Journal of child and adolescent psychopharmacology, 22(6), 423-431 (2013-01-31)
The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. This study was an open, prospective, observational study of youth with...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service